Automated and single-use technologies are offering companies the transparency and agility needed for the newer, more complex drugs in the pipeline, explains Mike D’Avanzo from Alcami.

While the benefits of continuous manufacturing have been well-documented, regulatory alignment and complex control systems remain barriers to universal adoption, notes Mike Fazio from L.B. Bohle.

The push for regionalized supply chains is having an impact on the CDMO landscape, with responsiveness and flexibility now considered equally important as efficiency and scale, notes Andrea Oro from ESTEVE CDMO.

As global volatility exposes the fragility of lean supply models, the industry is pivoting toward regionalized manufacturing and agile optionality to safeguard patient access.

In the current market, drug developers need to carefully balance sudden regulatory mandates with innovation while also managing costs and time efficiency, explains Meeta Kratz from Lonza Capsugel.

With major therapeutic indications close on the horizon, the industry must urgently address the prohibitive costs and manufacturing complexities currently blocking patient access to life-changing cures.

To secure the long-term continuity of global supply there needs to be a convergence of operational excellence and advanced chemistry, note Almac’s James Hurst and Prof. Tom Moody.

According to Maja Pedersen from FUJIFILM Biotechnologies, modularity, AI-driven compliance, and harmonized global networks are necessary to resolve complexity challenges in downstream processing.

In this brief guide to DCAT Week 2026, The Pharma Navigator explores some of the critical dialogues’ attendees can look forward to participating in during their stay in Manhattan.

As sponsors navigate the complexities of a global supply environment, partnering with CDMOs who can anticipate issues and optimize processes is essential to avoid unnecessary cost hurdles, notes Kent Payne from Wilmington PharmaTech.

According to Carrie Bracco from Novartis Contract Manufacturing, by leveraging large-scale infrastructure, embedded CMOs can help meet rising demand for localized manufacturing.

Technological innovations are allowing for improvements in the clinical trial sector and providing greater volumes of data; however, companies should be mindful to ensure they are measuring meaningful data.

No longer relegated to post-market safety monitoring, RWE is emerging as a critical strategic tool in early drug development, helping to de-risk pipelines, refine target product profiles, and optimize trial design.

By fully integrating support for ADC technologies into its Advanced Synthesis portfolio, Lonza is now able to offer phase-appropriate CDMO support for bioconjugates from discovery through clinical supply.

When approaching their clinical trials, sponsors need to balance the program’s needs with the tools and approaches they want to implement to ensure success, explains György Barta from Research Professionals.

An exposure-driven, translational approach, linking early ADME with biomarker discovery, can help teams define the therapeutic window long before lead candidate nomination, according to Hong Wan from BioDuro.

In this deep-dive panel discussion moderated by The Pharma Navigator, several experts map out the future of excipients, addressing everything from climate-driven disruption to the need for greater industry collaboration.

As chronic diseases rise globally, the bio/pharma industry is pivoting toward increasingly complex molecules that demand more sophisticated delivery strategies, which must be considered early on in development.

The raised funds, totaling USD 40 million, will be used to accelerate the company’s growth and to advance its robotic platform, Constellation, which enables flexible, scalable cell therapy manufacturing.

As demand for GLP-1 obesity drugs surges and affordability remains a competitive factor in the global weight-loss market, Eli Lilly slashes tirzepatide vial prices to boost access for self-pay patients.